Drug Trial Radar · NCT03417245
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
Last checked: Nov 19, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Mar 1, 2018
Primary completion
Jan 26, 2021
Study completion Jul 14, 2021
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: -To evaluate the efficacy of fitusiran compared to on-demand treatment with factor concentrates, as determined by the frequency of bleeding episodes. Secondary Objectives: * To evaluate the efficacy of fitusiran compared to on-demand treatment with factor concentrates, as determined by: * The frequency of spontaneous bleeding episodes. * The frequency of joint bleeding episodes. * Health-related quality of life (HRQOL) in participants \>=17 years of age. * To determine the frequency of bleeding episodes during the onset period. * To determine the safety and tolerability of fitusiran.
Conditions
- Hemophilia A
- Hemophilia B
Interventions
fitusiranDrug
by SC injection
factor concentratesDrug
by intravenous (IV) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy PeriodTime frame: From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest
- Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy PeriodTime frame: From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest
Locations
64 sites in 19 countries. Site status is shown where the registry gives one.
Investigational Site Number 0140
Little Rock, Arkansas
Investigational Site Number 128
Gainesville, Florida
Investigational Site Number 103
Tampa, Florida
Investigational Site Number 102
Chicago, Illinois
Investigational Site Number 119
New Orleans, Louisiana
Investigational Site Number 125
Ann Arbor, Michigan
Investigational Site Number 111
Las Vegas, Nevada
Investigational Site Number 110
Akron, Ohio
Investigational Site Number 6101
Camperdown, Australia
Investigational Site Number 6103
Murdoch, Australia
Investigational Site Number 6104
Prahran, Australia
Investigational Site Number 8604
Beijing, China
Investigational Site Number 8602
Guangzhou, China
Investigational Site Number 8605
Hangzhou, China
Investigational Site Number 8603
Shanghai, China
Investigational Site Number 8601
Tianjin, China
Investigational Site Number 4501
Copenhagen, Denmark
Investigational Site Number 3303
Lyon, France
Investigational Site Number 3305
Paris, France
Investigational Site Number 3301
Rouen, France
Investigational Site Number 4904
Berlin, Germany
Investigational Site Number 4905
Frankfurt am Main, Germany
Investigational Site Number 4906
Leipzig, Germany
Investigational Site Number 3602
Budapest, Hungary
Investigational Site Number 9102
Bangalore, India
Investigational Site Number 9104
Jaipur, India
Investigational Site Number 9106
Lucknow, India
Investigational Site Number 9109
Mumbai, India
Investigational Site Number 9108
Mumbai, India
Investigational Site Number 9111
Mumbai, India
Investigational Site Number 9103
Pune, India
Investigational Site Number 9105
Vellore, India
Investigational Site Number 9701
Ramat Gan, Israel
Investigational Site Number 3904
Padova, Italy
Investigational Site Number 8105
Isehara, Japan
Investigational Site Number 8104
Saitama, Japan
Investigational Site Number 6004
Ampang, Malaysia
Investigational Site Number 6002
Johor Bahru, Malaysia
Investigational Site Number 6003
Kota Kinabalu, Malaysia
Investigational Site Number 2701
Parktown, South Africa
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.